EGFR and non-small cell lung carcinoma: At the molecular level, mutations of EGFR promote the spontaneous dimerization and activation of this protein, and this contributes to the onset and progression of NSCLC.[4] NSCLC patients with certain EGFR mutations also have an increased risk of BM.[5, 6, 7] Osimertinib, an EGFR tyrosine kinase inhibitor (EGFR‐TKI), provides significant benefits to NSCLC patients with EGFR mutations, including those with BM, but these patients inevitably experience cancer progression because of the development of drug resistance.[8]